LIMN:NASDAQLiminatus Pharma, Inc. analysis

Liminatus Pharma is trading well below its 20‑day and 50‑day simple moving averages, with the 20‑day SMA just under the 50‑day SMA, indicating a bearish price structure. The RSI hovers around the low‑40s, suggesting neutral‑to‑weak momentum, while the MACD histogram has turned slightly positive, offering a faint bullish signal amid an overall bearish trend. Volume has been increasing and the 30‑day volatility exceeds 150%, underscoring extreme price swings. The stock’s beta is very low, implying minimal correlation with broader market moves, but the company faces a critical Nasdaq delisting notice that must be appealed by May 27, creating acute regulatory pressure.
Fundamentally, LIML reports zero revenue, negative operating cash flow, and a negative book value per share, with no dividends and a negative price‑to‑book ratio. The market cap is under $10 million, and the company’s pipeline is still pre‑clinical, making earnings visibility virtually non‑existent. The combination of a speculative growth story, severe liquidity constraints, and imminent compliance risk renders the stock highly speculative at best.